FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kathleen Pritchard

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Howard A Burris; Edmond Chouinard; Michael Gnant; Gabriel N Hortobagyi; Anna Komorowski; Fabienne Lebrun; Patrick Neven; Katarina Petrakova; Martine Piccart; Kathleen I Pritchard; Jean-Francois Ricci; Hope S Rugo; Tarek Sahmoud; Tetiana Taran; Robyn Young; Jose Baselga; Hounayda Bauly; J Thaddeus Beck; Lee Bennett; Shinzaburo Noguchi
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Michael Gnant; Peyman Hadji; Lowell L Hart; Gabriel N Hortobagyi; Hiroji Iwata; David Lebwohl; Hirofumi Mukai; Shinzaburo Noguchi; Martine Piccart; Jose Baselga; Howard A Burris; Mario Campone; Janice Eakle; Mona El-Hashimy; Matthias Geberth; Shantha Rao; Hope S Rugo; Tarek Sahmoud; Tetiana Taran; Kathleen I Pritchard
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Paul E Goss; James N Ingle; David B Johnson; Istvan Lang; Pedro E R Liedke; Edith A Perez; Kathleen I Pritchard; Manuela Rabaglio; Rafat H Ansari; G Thomas Budd; Haji Chalchal; Judy-Anne W Chapman; David P D'Souza; Catherine Elliott; Matthew J Ellis; Karen Gelmon; George W Sledge; Silvana Spadafora; Vered Stearns; Richard Tozer; Lois E Shepherd
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kathleen Pritchard (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Howard A Burris; Edmond Chouinard; Michael Gnant; Gabriel N Hortobagyi; Anna Komorowski; Fabienne Lebrun; Patrick Neven; Katarina Petrakova; Martine Piccart; Kathleen I Pritchard; Jean-Francois Ricci; Hope S Rugo; Tarek Sahmoud; Tetiana Taran; Robyn Young; Jose Baselga; Hounayda Bauly; J Thaddeus Beck; Lee Bennett; Shinzaburo Noguchi
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Cancer 2013;119(10):1908-15.
2013: Michael Gnant; Peyman Hadji; Lowell L Hart; Gabriel N Hortobagyi; Hiroji Iwata; David Lebwohl; Hirofumi Mukai; Shinzaburo Noguchi; Martine Piccart; Jose Baselga; Howard A Burris; Mario Campone; Janice Eakle; Mona El-Hashimy; Matthias Geberth; Shantha Rao; Hope S Rugo; Tarek Sahmoud; Tetiana Taran; Kathleen I Pritchard
Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2.
Journal of the National Cancer Institute 2013;105(9):654-63.
2013: Paul E Goss; James N Ingle; David B Johnson; Istvan Lang; Pedro E R Liedke; Edith A Perez; Kathleen I Pritchard; Manuela Rabaglio; Rafat H Ansari; G Thomas Budd; Haji Chalchal; Judy-Anne W Chapman; David P D'Souza; Catherine Elliott; Matthew J Ellis; Karen Gelmon; George W Sledge; Silvana Spadafora; Vered Stearns; Richard Tozer; Lois E Shepherd
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(11):1398-404.
2013: Paul E Goss; James N Ingle; Robert B Livingston; Silvana Martino; Hyman Muss; Edith A Perez; Kathleen I Pritchard; Nicholas J Robert; Lois E Shepherd; David A Cameron; Y Chavarri-Guerra; Nancy E Davidson; T Whelan; Dongsheng Tu
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(2):355-61.
2013: Otto Metzger-Filho; Edith A Perez; Kathleen I Pritchard; Kamal S Saini; Sergio D Simon; Ian Smith; Michael Untch; Antonio C Wolff; Binghe Xu; Gursel Aktan; Jose Baselga; José Bines; Frances Boyle; Ian Bradbury; Evandro de Azambuja; Veerle Van Dooren; Christian Jackisch; Istvan Lang; Martine Piccart-Gebhart
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
The oncologist 2013;18(2):134-40.
2013: Paul E Goss; William Gradishar; Manfred Kaufmann; Deborah Lindquist; Miguel Martin; Beverly Moy; Joyce O'Shaughnessy; Martine Piccart-Gebhart; Kathleen I Pritchard; Erica Rappold; Ian E Smith; Lisa S Williams; Gursel Aktan; Frances Boyle; Aman U Buzdar; Yanin Chavarri-Guerra; Bent Ejlertsen; Dianne M Finkelstein; Pierre Fumoleau
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
The lancet oncology 2013;14(1):88-96.
2012: M Clemons; K A Gelmon; Kathleen I Pritchard; A H G Paterson
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
Current oncology (Toronto, Ont.) 2012;19(5):259-68.
2012: John R Mackey; Deanna M McLeod; Alexander H G Paterson; Stephen K Chia; Loretta L Collins; Karen A Gelmon; Robert S Kerbel; Daniel Rayson; André Robidoux; Sunil Verma; Kathleen I Pritchard
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.
Cancer treatment reviews 2012;38(6):673-88.
2012: Stephen K Chia; Matthew J Ellis; Shan Jiang; Samuel Leung; Elaine Mardis; Joel S Parker; Charles M Perou; Kathleen I Pritchard; Lois E Shepherd; Dongsheng Tu; Karen Ung; Tammi Vickery; Philip S Bernard; Vivien H Bramwell; Torsten O Nielsen
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(16):4465-72.
2012: Catherine M Kelly; Kathleen I Pritchard
Personalized medicine: what exactly is it and can we truly measure it?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2173-4.
2012: Kathleen I Pritchard; Athena S Ruste
Adjuvant endocrine therapy for breast cancer: a commentary.
Oncology (Williston Park, N.Y.) 2012;26(6):568, 570.
2012: Kathleen I Pritchard; Berta Sousa
ABC 1 (1st International consensus guidelines for advanced breast cancer): a positive step.
Breast (Edinburgh, Scotland) 2012;21(3):225-6.
2012: Kathleen I Pritchard; Wendy Shelley; Peter Lovrics; David McCready; Frances P O'Malley; Francisco Perera; Audley Bodurtha; Nancy Down; Leela Elavathil; Ralph George; Karen Yvonne Gulenchyn; Nicole Hodgson; Claire M B Holloway; Jim A Julian; Mark N Levine
Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(12):1274-9.
2012: Maggie C U Cheang; Stephen K Chia; Sherri Davies; Carole Davis; Mark T W Ebbert; Matthew J Ellis; Shan Jiang; Samuel Leung; Mark N Levine; Joel S Parker; Charles M Perou; Kathleen I Pritchard; Lois E Shepherd; Inge J Stijleman; Dongsheng Tu; K David Voduc; Philip S Bernard; Torsten O Nielsen
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2402-12.
2012: Catherine M Kelly; Kathleen I Pritchard
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Journal of the National Cancer Institute 2012;104(6):427-8.
2012: Javier Cortés; Hernan Cortes-Funes; Suzette Delaloge; David T Bollag; Mireia Caralt; Jean-Yves Pierga; Kathleen I Pritchard; David W Miles
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
European journal of cancer (Oxford, England : 1990) 2012;48(4):475-81.
2012: José Baselga; J Thaddeus Beck; Howard A Burris; Mario Campone; Ines Deleu; Michael Gnant; Thomas Bachelot; Yoshinori Ito; Fabienne Lebrun; David Lebwohl; Pabak Mukhopadhyay; Shinzaburo Noguchi; Alejandra Perez; Martine Piccart; Kathleen I Pritchard; Hope S Rugo; Tarek Sahmoud; Luc Vittori; Zhiying Xu; Denise Yardley; Gabriel N Hortobagyi
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
The New England journal of medicine 2012;366(6):520-9.
2012: Pernille Braemer Hertel; Maj-Britt Jensen; Shan Jiang; Eva Balslev; Annette Bartels; Nils Brünner; Bent Ejlertsen; Frances P O'Malley; Kathleen I Pritchard; Lois E Shepherd; Dongsheng Tu; Torsten O Nielsen
TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Breast cancer research and treatment 2012;132(1):225-34.
2012: Christoph Thomssen; Laura Biganzoli; Hernan Cortes-Funes; Anja Duenne; Bella Kaufman; Katarína Petráková; Jean-Yves Pierga; Kathleen I Pritchard; Ian Smith
First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study.
Oncology 2012;82(4):218-27.
2011: Ian Smith; Christoph Thomssen; Silvana Saracchini; Laura Biganzoli; Hernan Cortes-Funes; Anja-Alexandra Duenne; Bella Nisenbaum; Ignacio Pelaez; Jean-Yves Pierga; Kathleen I Pritchard
Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial.
Breast cancer research and treatment 2011;130(1):133-43.
2011: Kathleen I Pritchard; Lois E Shepherd; Ted A Vandenberg; D Walde; Timothy J Whelan; Carolyn F Wilson; Jacques Cantin; Judith-Anne W Chapman; Susan F Dent; Brian Findlay; Paul E Goss; Lei Han; Brian D Norris; Susan E O'Reilly; Ettie Piura; Michael N Pollak
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(29):3869-76.
2011: Allan Lipton; Kathleen I Pritchard; Lois E Shepherd; Carolyn F Wilson; Suhail M Ali; Judy-Anne W Chapman; Laurence Demers; Lei Han; Kim Leitzel; Michael Pollak
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(27):3605-10.
2011: Frances P O'Malley; Lois E Shepherd; Dongsheng Tu; Irene L Andrulis; Vivien H C Bramwell; S Chia; D Huntsman; Mark N Levine; Kathleen I Pritchard
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
Breast cancer research and treatment 2011;128(2):401-9.
2011: Kathleen I Pritchard
Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?
Breast cancer research and treatment 2011;127(2):587-8.
2011: Kathleen I Pritchard; Berta Sousa
Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1651-2.
2011: Susan F Dent; Rania Gaspo; Michelle Kissner; Kathleen I Pritchard
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Breast cancer research and treatment 2011;126(2):295-310.
2011: Luca Gianni; Urania Dafni; Richard D Gelber; Evandro Azambuja; Susanne Muehlbauer; Aron Goldhirsch; Michael Untch; Ian Smith; José Baselga; Christian Jackisch; David Cameron; Max Mano; José Luiz Pedrini; Andrea Veronesi; Cesar Mendiola; Anna Pluzanska; Vladimir Semiglazov; Eduard Vrdoljak; Michael J Eckart; Zhenzhou Shen; George Skiadopoulos; Marion Procter; Kathleen I Pritchard; Martine J Piccart-Gebhart; Richard Bell
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
The lancet oncology 2011;12(3):236-44.
2011: Pamela J Goodwin; Vuk Stambolic; Julie Lemieux; Bingshu E Chen; Wendy R Parulekar; Karen A Gelmon; Dawn L Hershman; Timothy J Hobday; Jennifer A Ligibel; Ingrid A Mayer; Kathleen I Pritchard; Timothy J Whelan; Priya Rastogi; Lois E Shepherd
Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Breast cancer research and treatment 2011;126(1):215-20.
2011: Lawson Eng; Irada Ibrahim-zada; Hamdi Jarjanazi; Sevtap Savas; Mehran Meschian; Kathleen I Pritchard; Hilmi Ozcelik
Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.
BMC medical genomics 2011;4():18.
2010: Louise Bordeleau; Kathleen I Pritchard; Charles L Loprinzi; Marguerite Ennis; Olivera Jugovic; David Warr; Rashida Haq; Pamela J Goodwin
Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(35):5147-52.
2010: James N Ingle; Daniel J Schaid; Paul E Goss; Mohan Liu; Taisei Mushiroda; Judy-Anne W Chapman; Michiaki Kubo; Gregory D Jenkins; Anthony Batzler; Lois Shepherd; Joseph Pater; Liewei Wang; Matthew J Ellis; Vered Stearns; Daniel C Rohrer; Matthew P Goetz; Kathleen I Pritchard; David A Flockhart; Yusuke Nakamura; Richard M Weinshilboum
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4674-82.
2010: Kathleen I Pritchard; Janusz Rolski; Zsuzsanna Papai; Louis Mauriac; Fatima Cardoso; Jose Chang; Lawrence Panasci; Carmen Ianuli; Zsuzsanna Kahan; Kenjiro Fukase; Justin P O Lindemann; Merran P Macpherson; Patrick Neven
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Breast cancer research and treatment 2010;123(2):453-61.
2010: Pamela J Goodwin; Kathleen I Pritchard
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(21):3405-7.
2010: Kathleen I Pritchard
High levels of uPA and PAI-1 predict a good response to anthracyclines.
Breast cancer research and treatment 2010;121(3):625-6.
2010: Daphne T Tsoi; Corwyn Rowsell; Caitlin McGregor; Catherine M Kelly; Sunil Verma; Kathleen I Pritchard
Disseminated tumor embolism from breast cancer leading to multiorgan failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):e180-3.
2010: Saira Nasim; Kathleen I Pritchard
Adjuvant hormonal therapy for premenopausal breast cancer: incorporating clinical experience.
Oncology (Williston Park, N.Y.) 2010;24(4):332, 337, 340.
2010: Kathleen I Pritchard
Optimizing the delivery of targeted research: an opportunity for comparative effectiveness research.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(7):1089-91.
2010: Nan Soon Wong; Robert A Buckman; Mark Clemons; Shailendra Verma; Susan Dent; Maureen Trudeau; Kathie Roche; John Ebos; Robert Kerbel; Gerrit E Deboer; Donald J A Sutherland; Urban Emmenegger; Joyce M Slingerland; Sandra Gardner; Kathleen I Pritchard
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):723-30.
2010: Kathleen I Pritchard
Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Breast cancer research : BCR 2010;12 Suppl 4():S18.
2010: Sara K Taylor; Stephen Chia; Susan Dent; Mark Clemons; Mark Agulnik; Pamela Grenci; Lisa Wang; Amit M Oza; Percy Ivy; Kathleen I Pritchard; Natasha B Leighl
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
The oncologist 2010;15(8):810-8.
2010: Catherine M Kelly; Ellen Warner; Daphne T Tsoi; Sunil Verma; Kathleen I Pritchard
Review of the clinical studies using the 21-gene assay.
The oncologist 2010;15(5):447-56.
2010: Daphne T Tsoi; Miho Inoue; Catherine M Kelly; Sunil Verma; Kathleen I Pritchard
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
The oncologist 2010;15(5):457-65.
2010: Catherine M Kelly; David N Juurlink; Tara Gomes; Minh Duong-Hua; Kathleen I Pritchard; Peter C Austin; Lawrence F Paszat
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
BMJ (Clinical research ed.) 2010;340():c693.
2010: Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter M Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
The lancet oncology 2010;11(1):55-65.
2010: Amadeo M Parissenti; Judy-Anne W Chapman; Harriette J Kahn; Baoqing Guo; Lei Han; Patti O'Brien; Mark P Clemons; Roberta Jong; Rebecca Dent; Barbara Fitzgerald; Kathleen I Pritchard; Lois E Shepherd; Maureen E Trudeau
Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
Breast cancer research and treatment 2010;119(2):347-56.
2009: Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Lancet 2009;374(9707):2055-63.
2009: Kathleen I Pritchard
Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
The oncologist 2009;14(10):959-62.
2009: Kathleen I Pritchard
Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(24):3875-6.
2009: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Jarley Koo; Nicky Hood
Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3757-63.
2009: Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade Iii; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3235-58.
2009: Frances P O'Malley; S Chia; Dongsheng Tu; Lois E Shepherd; Mark N Levine; Vivien H C Bramwell; Irene L Andrulis; Kathleen I Pritchard
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
Journal of the National Cancer Institute 2009;101(9):644-50.
2009: Pamela J Goodwin; Marguerite Ennis; Mala Bahl; I George Fantus; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Nicky Hood
High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.
Breast cancer research and treatment 2009;114(3):517-25.
2009: Vuk Stambolic; James R Woodgett; I George Fantus; Kathleen I Pritchard; Pamela J Goodwin
Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?
Breast cancer research and treatment 2009;114(2):387-9.
2009: Shelly S Lo; Kathleen I Pritchard; Patricia Robinson; Kathy S Albain
Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings.
Cancer treatment and research 2009;147():1-29.
2009: Kathleen I Pritchard
Tailored targeted therapy for all: a realistic and worthwhile objective against.
Breast cancer research : BCR 2009;11 Suppl 3():S8.
2009: Kathleen I Pritchard
Guidelines, consensus conferences and overviews (meta-analysis).
Cancer treatment and research 2009;151():63-76.
2009: Kathleen I Pritchard
Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Oncology (Williston Park, N.Y.) 2009;23(1):27-33.
2009: Tao Deng; Jeff C Liu; Kathleen I Pritchard; Andrea Eisen; Eldad Zacksenhaus
Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):119-30.
2008: Kathleen I Pritchard
Endocrine symptoms to predict risk of recurrence?
The lancet oncology 2008;9(12):1117-9.
2008: Fred Saad; Jonathan D Adachi; Jacques P Brown; Leah A Canning; Karen A Gelmon; Robert G Josse; Kathleen I Pritchard
Cancer treatment-induced bone loss in breast and prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5465-76.
2008: Yolanda Madarnas; Maureen Trudeau; Jacob A Franek; David McCready; Kathleen I Pritchard; Hans Messersmith
Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.
Cancer treatment reviews 2008;34(6):539-57.
2008: Julie Lemieux; Pamela J Goodwin; Kathleen I Pritchard; Karen A Gelmon; Louise J Bordeleau; Thierry Duchesne; Stéphanie Camden; Caroline H Speers
Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(27):4458-65.
2008: Ian S Dayes; Mark N Levine; Jim A Julian; Kathleen I Pritchard; David P D'Souza; Lyn Kligman; Donnalue Reise; Jennifer A Wiernikowski; L Bonilla; Timothy J Whelan
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial.
Breast cancer research and treatment 2008;110(2):337-42.
2008: Kathleen I Pritchard
Antihormone therapy in recurrent metastatic breast cancer.
JAMA : the journal of the American Medical Association 2008;299(23):2745; author reply 2745.
2008: James N Ingle; Dongsheng Tu; Joseph L Pater; Hyman Muss; Silvana Martino; Nicholas J Robert; Martine J Piccart; M Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(5):877-82.
2008: Bindi Dhesy-Thind; Kathleen I Pritchard; Hans Messersmith; Frances P O'Malley; Leela Elavathil; Maureen Trudeau
HER2/neu in systemic therapy for women with breast cancer: a systematic review.
Breast cancer research and treatment 2008;109(2):209-29.
2008: Paul E Goss; James N Ingle; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Dongsheng Tu
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1948-55.
2008: Hyman Muss; Dongsheng Tu; James N Ingle; Silvana Martino; Nicholas J Robert; Joseph L Pater; Timothy J Whelan; Michael J Palmer; Martine J Piccart; Lois E Shepherd; Kathleen I Pritchard; Zhi He; Paul E Goss
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1956-64.
2008: Kathleen I Pritchard
Should observational studies be a thing of the past?
Journal of the National Cancer Institute 2008;100(7):451-2.
2008: Andrea Eisen; Maureen Trudeau; Wendy Shelley; Hans Messersmith; Kathleen I Pritchard
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Cancer treatment reviews 2008;34(2):157-74.
2008: Kathleen I Pritchard; Hans Messersmith; Leela Elavathil; Maureen Trudeau; Frances P O'Malley; Bindi Dhesy-Thind
HER-2 and topoisomerase II as predictors of response to chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(5):736-44.
2008: Kathleen I Pritchard
Combining endocrine agents with chemotherapy: which patients and what sequence?
Cancer 2008;112(3 Suppl):718-22.
2008: Steven E Come; Aman U Buzdar; James N Ingle; Stephen R D Johnston; Angela Brodie; R Charles Coombes; William R Miller; Kathleen I Pritchard; Eric P Winer; Jo Anne Zujewski; Paul E Goss
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Cancer 2008;112(3 Suppl):673-8.
2008: Federica Cuppone; Emilio Bria; Sunil Verma; Kathleen I Pritchard; Sonal Gandhi; Paolo Carlini; Michele Milella; Cecilia Nisticò; Edmondo Terzoli; Francesco Cognetti; Diana Giannarelli
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Cancer 2008;112(2):260-7.
2008: Kathleen I Pritchard
Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?
Breast cancer research : BCR 2008;10 Suppl 4():S23.
2008: Michael Crump; Stefan Gluck; Dongsheng Tu; Doug Stewart; Mark Levine; Peter Kirkbride; Janet Dancey; Susan O'Reilly; Tsiporah Shore; Stephen Couban; Caroline Girouard; Susan Marlin; Lois Shepherd; Kathleen I Pritchard
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):37-43.
2007: Kathleen I Pritchard
Adjuvant therapy of the very young woman.
Breast (Edinburgh, Scotland) 2007;16 Suppl 2():S136-46.
2007: Nan Soon Wong; Wei Seong Ooi; Kathleen I Pritchard
Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3787.
2007: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Triple-negative breast cancer: clinical features and patterns of recurrence.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4429-34.
2007: Kathleen I Pritchard
Risk of chemotherapy induced menopause: more detailed data will lead to improved quality of life.
European journal of cancer (Oxford, England : 1990) 2007;43(11):1644-5.
2007: Clifford Hudis; William E Barlow; Joseph P Costantino; Robert J Gray; Kathleen I Pritchard; Judith-Anne W Chapman; Joseph A Sparano; Sally Hunsberger; Rebecca A Enos; Richard D Gelber; Jo Anne Zujewski
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2127-32.
2007: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2006-11.
2007: Domingo G Pérez; Katherine M Zahasky; Charles L Loprinzi; Jeff Sloan; Paul J Novotny; Debra L. Barton; Kathleen I Pritchard
Tamoxifen-associated hot flashes in women.
Supportive cancer therapy 2007;4(3):152-6.
2007: Kathleen I Pritchard
Adjuvant therapy for breast cancer: we are solving the puzzle, but pieces are still missing.
Journal of the National Cancer Institute 2007;99(7):494-5.
2007: James R Wright; Yee C Ung; Jim A Julian; Kathleen I Pritchard; Timothy J Whelan; Column Smith; Barbara Szechtman; Wilson Roa; Liam Mulroy; Leona Rudinskas; Bruno Gagnon; Gordon Okawara; Mark N Levine
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(9):1027-32.
2006: Jianhua Liu; Dongsheng Tu; Janet Dancey; Leonard Reyno; Kathleen I Pritchard; Joseph L Pater; Lesley K Seymour
Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
Breast cancer research and treatment 2006;100(3):263-71.
2006: Mark Clemons; George Dranitsaris; Wei S Ooi; Geetha Yogendran; Tatjana Sukovic; Betty Y L Wong; Sunil Verma; Kathleen I Pritchard; Maureen Trudeau; David E C Cole
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(30):4895-900.
2006: James N Ingle; Dongsheng Tu; Joseph L Pater; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Paul E Goss
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Breast cancer research and treatment 2006;99(3):295-300.
2006: Edith A Perez; Robert G Josse; Kathleen I Pritchard; James N Ingle; Silvana Martino; Brian Findlay; Tamara N Shenkier; Richard G Tozer; Michael J Palmer; Lois E Shepherd; Shifang Liu; Dongsheng Tu; Paul E Goss
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3629-35.
2006: Harriette J Kahn; Wedad M Hanna; Judith-Anne W Chapman; Maureen Trudeau; H Lavina A Lickley; Betty G Mobbs; David Murray; Kathleen I Pritchard; Carol A Sawka; David R McCready; Alexander Marks
Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
The breast journal 2006;12(4):294-301.
2006: Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H C Bramwell; Mark N Levine
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
The New England journal of medicine 2006;354(20):2103-11.
2006: Eva Grunfeld; Mark N Levine; Jim A Julian; Douglas Coyle; Barbara Szechtman; Doug Mirsky; Shailendara Verma; Susan Dent; Carol Sawka; Kathleen I Pritchard; David Ginsburg; Marjorie Wood; Timothy Whelan
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):848-55.
2006: Timothy J Whelan; Kathleen I Pritchard
Managing patients on endocrine therapy: focus on quality-of-life issues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1056s-1060s.
2006: Steven E Come; Aman U Buzdar; James N Ingle; Carlos L Arteaga; Myles Brown; Mitch Dowsett; Susan G Hilsenbeck; Rakesh Kumar; Stephen R D Johnston; Adrian V Lee; Soonmyung Paik; Kathleen I Pritchard; Eric P Winer; Carol Hart
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):997s-1000s.
2006: Kathleen I Pritchard; Beth L Abramson
Cardiovascular health and aromatase inhibitors.
Drugs 2006;66(13):1727-40.
2006: Judith-Anne W Chapman; H Lavina A Lickley; Maureen Trudeau; Wedad M Hanna; Harriette J Kahn; David Murray; Carol A Sawka; Betty G Mobbs; David R McCready; Kathleen I Pritchard
Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
The breast journal 2006;12(1):37-47.
2005: Kathleen I Pritchard
Adjuvant endocrine therapies for pre-/perimenopausal women.
Breast (Edinburgh, Scotland) 2005;14(6):547-54.
2005: Mala Bahl; Marguerite Ennis; Ian F Tannock; Janet E Hux; Kathleen I Pritchard; Jarley Koo; Pamela J Goodwin
Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.
Breast cancer research and treatment 2005;94(2):135-44.
2005: Nan Soon Wong; Kathleen I Pritchard
A review of exemestane in the management of breast cancer.
Expert opinion on pharmacotherapy 2005;6(13):2353-63.
2005: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; David A Cameron; Michael J Palmer; Joseph L Pater
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Journal of the National Cancer Institute 2005;97(17):1262-71.
2005: Pamela J Goodwin; Marguerite Ennis; I George Fantus; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Nicky Hood
Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6037-42.
2005: Wendy R Parulekar; Andrew G Day; Jon Ottaway; Lois E Shepherd; Maureen E Trudeau; Vivien H C Bramwell; Mark Levine; Kathleen I Pritchard
Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6002-8.
2005: Mark N Levine; Kathleen I Pritchard; Vivien H C Bramwell; Lois E Shepherd; Dongsheng Tu; Nancy Paul
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5166-70.
2005: Kathleen I Pritchard
Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4850-2.
2005: James R Wright; Kathie Roche; Bobbi Smuck; Janet Cormier; Suzanne Cecchetto; Marisa Akow; Susan Pilatzke; Kathleen I Pritchard
Estimating per patient funding for cancer clinical trials: an Ontario based survey.
Contemporary clinical trials 2005;26(4):421-9.
2005: Eric P Winer; Clifford Hudis; Harold J Burstein; Antonio C Wolff; Kathleen I Pritchard; James N Ingle; Rowan T Chlebowski; Richard D Gelber; Stephen B Edge; Julie R Gralow; Melody A Cobleigh; Eleftherios P Mamounas; Lori J Goldstein; Timothy J Whelan; Trevor J Powles; John Bryant; Cheryl Perkins; Judy Perotti; Susan Braun; Amy S Langer; George P Browman; Mark R Somerfield
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):619-29.
2005: Maureen Trudeau; Kathleen I Pritchard; Judith-Anne W Chapman; Wedad M Hanna; Harriette J Kahn; David Murray; Carol A Sawka; Betty G Mobbs; Irene L Andrulis; David R McCready; H Lavina A Lickley
Prognostic factors affecting the natural history of node-negative breast cancer.
Breast cancer research and treatment 2005;89(1):35-45.
2004: Pamela J Goodwin; Marguerite Ennis; Louise J Bordeleau; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Nicky Hood
Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4184-92.
2004: Kathleen I Pritchard
Is exercise effective in reducing the risk of breast cancer in postmenopausal women?
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(5):787.
2004: Shelley B Bull; Hilmi Ozcelik; Dushanthi Pinnaduwage; Martin E Blackstein; Donald A J Sutherland; Kathleen I Pritchard; Anjela Tzontcheva; Saul Sidlofsky; Wedad M Hanna; Ali H Qizilbash; Mary E Tweeddale; Sheldon Fine; David R McCready; Irene L Andrulis
The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):86-96.
2003: Kathleen I Pritchard
The best use of adjuvant endocrine treatments.
Breast (Edinburgh, Scotland) 2003;12(6):497-508.
2003: Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
The New England journal of medicine 2003;349(19):1793-802.
2003: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Jarley Koo; Maureen E Trudeau; Nicky Hood
Diet and breast cancer: evidence that extremes in diet are associated with poor survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2500-7.
2003: Eric P Winer; Clifford Hudis; Harold J Burstein; John Bryant; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Richard Gelber; Julie R Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2597-9.
2003: Kathleen I Pritchard
Adjuvant therapy for early breast cancer: where do we stand today?
MedGenMed : Medscape general medicine 2003;5(2):17.
2003: Louise J Bordeleau; John Paul Szalai; Marguerite Ennis; Molyn Leszcz; Michael Speca; Rami Sela; Richard Doll; Harvey Max Chochinov; Margaret Navarro; Andrew Arnold; Kathleen I Pritchard; Andrea Bezjak; Hilary A Llewellyn-Thomas; Carol A Sawka; Pamela J Goodwin
Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):1944-51.
2003: M Elisabeth Del Giudice; Carol A Sawka; Kathleen I Pritchard; Hilary A Llewellyn-Thomas; Maureen Trudeau; J E Lewis; Edmee Franssen
Hormone replacement therapy after treatment for breast cancer: physicians' attitudes towards randomized trials.
Breast cancer research and treatment 2003;79(2):213-23.
2003: Joseph L Pater; Kathleen I Pritchard
Optimal chemotherapy for women with breast cancer: the plot thickens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):963-4.
2003: Eileen Rakovitch; Edmee Franssen; John Kim; Ida Ackerman; Jean-Philippe Pignol; Lawrence Paszat; Kathleen I Pritchard; Cindy Ho; Donald A Redelmeier
A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer.
Breast cancer research and treatment 2003;77(3):285-93.
2003: Kathleen I Pritchard; Mark N Levine; Dongsheng Tu
neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(3):399-400.
2003: Kathleen I Pritchard
Endocrine therapy of advanced disease: analysis and implications of the existing data.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):460S-7S.
2003: Steven E Come; Aman U Buzdar; Carlos L Arteaga; Angela Brodie; Nancy E Davidson; Mitch Dowsett; James N Ingle; Stephen R D Johnston; Adrian V Lee; C Kent Osborne; Kathleen I Pritchard; Victor G Vogel; Eric P Winer; Carol S Hart
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):443S-6S.
2002: Kathleen I Pritchard
Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(24):4611-4.
2002: Eric P Winer; Clifford Hudis; Harold J Burstein; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Julie R Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3317-27.
2002: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Warren Hartwick; Barry Hoffma; Nicky Hood
Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes.
Breast cancer research and treatment 2002;74(1):65-76.
2002: Kathleen I Pritchard; Humaira Khan; Mark Levine
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;166(8):1017-22.
2002: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Maureen E Trudeau; Jarley Koo; Yolanda Madarnas; Warren Hartwick; Barry Hoffman; Nicky Hood
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):42-51.
2001: Kathleen I Pritchard
The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4356s-4359s; discussion 4411s-4412s.
2001: Louise J Bordeleau; Eileen Rakovitch; David M J Naimark; Kathleen I Pritchard; Ida Ackerman; Carol A Sawka
A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis.
Cancer 2001;92(1):23-9.
2001: R E Myers; M Johnston; Kathleen I Pritchard; M Levine; T Oliver
Baseline staging tests in primary breast cancer: a practice guideline.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2001;164(10):1439-44.
2000: BD Norris; Kathleen I Pritchard; K James; J Myles; K Bennett; S Marlin; JR Skillings; Brian Findlay; Theodore A Vandenberg; P Goss; Jean Latreille; Leona Rudinskas; WS Lofters; Maureen Trudeau; David Osoba; A Rodgers
Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2385-94.
1999: V H Bramwell; Kathleen I Pritchard
Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?
European journal of cancer (Oxford, England : 1990) 1999;35(12):1625-7.
1999: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; Maureen E Trudeau; Nicky Hood
Risk of menopause during the first year after breast cancer diagnosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2365-70.
1999: Pamela J Goodwin; Kathleen I Pritchard; D Spiegel
The Fox guarding the clinical trial: internal vs. external validity in randomized studies.
Psycho-oncology 1999;8(3):275.
1999: Pamela J Goodwin; Marguerite Ennis; Kathleen I Pritchard; David R McCready; Jarley Koo; Saul Sidlofsky; Maureen E Trudeau; Nicky Hood; S Redwood
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):120-9.
1998: R Santen; Kathleen I Pritchard; H Burger
The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer.
Obstetrical & gynecological survey 1998;53(10 Suppl):S1-83.
1998: Mark N Levine; Vivien H C Bramwell; Kathleen I Pritchard; BD Norris; Lois E Shepherd; Hakam Abu-Zahra; Brian Findlay; David Warr; D Bowman; J Myles; Andrew Arnold; Theodore A Vandenberg; R MacKenzie; J Robert; Jon Ottaway; M Burnell; C K Williams; Dongsheng Tu
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2651-8.
1998: Kathleen I Pritchard
Is tamoxifen effective in prevention of breast cancer?
Lancet 1998;352(9122):80-1.
1998: Ellen Warner; D Hedley; Irene L Andrulis; R Myers; Maureen Trudeau; David Warr; Kathleen I Pritchard; Martin E Blackstein; Paul E Goss; Edmee Franssen; K Roche; S Knight; S Webster; R A Fraser; S Oldfield; W Hill; R Kates
Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(6):1451-7.
1998: George Browman; TE Newman; E Ann Mohide; I D Graham; Mark N Levine; Kathleen I Pritchard; William K Evans; Jean Maroun; D I Hodson; M S Carey; Donald H Cowan
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1226-31.
1998: Kathleen I Pritchard
Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Cancer treatment and research 1998;94():158-80.
1997: Valerie A Palda; Hilary A Llewellyn-Thomas; RG Mackenzie; Kathleen I Pritchard; C D Naylor
Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(10):3192-200.
1997: M Elisabeth Del Giudice; Molyn Leszcz; Kathleen I Pritchard; L Vincent; P Goodwin
Attitudes of Canadian oncology practitioners toward psychosocial interventions in clinical and research settings in women with breast cancer.
Psycho-oncology 1997;6(3):178-89.
1997: Kathleen I Pritchard
Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management?
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S11-4.
1997: Carol A Sawka; Kathleen I Pritchard; W Shelley; G DeBoer; A H Paterson; J W Meakin; D J Sutherland
A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1.
Breast cancer research and treatment 1997;44(3):211-5.
1997: Michael Crump; Carol A Sawka; G DeBoer; R B Buchanan; J N Ingle; J Forbes; J W Meakin; W Shelley; Kathleen I Pritchard
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
Breast cancer research and treatment 1997;44(3):201-10.
1997: Kathleen I Pritchard; A H Paterson; S Fine; N A Paul; Benny Zee; Lois E Shepherd; Hakam Abu-Zahra; J Ragaz; Margaret A Knowling; Mark N Levine; S Verma; D Perrault; P L Walde; Vivien H C Bramwell; M Poljicak; Norman F Boyd; David Warr; BD Norris; D Bowman; G R Armitage; H Weizel; R A Buckman
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2302-11.
1997: Charles Catzavelos; N Bhattacharya; Yee C Ung; J A Wilson; L Roncari; Charanjit Sandhu; P Shaw; H Yeger; I Morava-Protzner; Linda Kapusta; Edmee Franssen; Kathleen I Pritchard; Joyce M Slingerland
Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.
Nature medicine 1997;3(2):227-30.
1997: George Browman; Mark N Levine; I Graham; Timothy Whelan; Carol Sawka; Kathleen I Pritchard; Alejandro R Jadad; TE Newman
The clinical practice guideline: an evolving health care technology.
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC 1997;1(1):7-8.
1997: P E Goss; S Fine; K Gelmon; Leona Rudinskas; Jon Ottaway; J Myles; K James; K Paul; A Rodgers; Kathleen I Pritchard
Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 1997;41(1):53-60.
1996: J W Chapman; D Murray; David R McCready; Wedad M Hanna; H J Kahn; H Lavina A Lickley; Maureen E Trudeau; B G Mobbs; Carol A Sawka; EB Fish; Kathleen I Pritchard
An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer?
European journal of cancer (Oxford, England : 1990) 1996;32A(11):1949-56.
1996: Kathleen I Pritchard; A H Paterson; N A Paul; Benny Zee; S Fine; Joseph L Pater
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2731-7.
1996: D Perrault; Elizabeth A Eisenhauer; Kathleen I Pritchard; L Panasci; B Norris; T Vandenberg; B Fisher
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2709-12.
1996: Kathleen I Pritchard
Postmenopausal breast cancer: is the short-term pain worth the long-term gain?
Lancet 1996;347(9008):1057-8.
1996: J W Chapman; B G Mobbs; David R McCready; H Lavina A Lickley; Maureen E Trudeau; Wedad M Hanna; H J Kahn; Carol A Sawka; EB Fish; Kathleen I Pritchard
An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays.
The Journal of steroid biochemistry and molecular biology 1996;57(5-6):323-8.
1996: J A Roy; Carol A Sawka; Kathleen I Pritchard
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):997-1006.
1996: Kathleen I Pritchard; J A Roy; Carol A Sawka
Sex hormones and breast cancer: the issue of hormone replacement.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1996;140():285-93.
1996: Pamela J Goodwin; Molyn Leszcz; J Koopmans; A Arnold; R Doll; H Chochinov; M Navarro; K Butler; Kathleen I Pritchard
Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Breast-Expressive Supportive Therapy study.
Cancer treatment reviews 1996;22 Suppl A():91-6.
1995: Carol A Sawka; Kathleen I Pritchard; H Lavina A Lickley; G A Oldfield; Judith-Anne W Chapman; G G Allen; B G Mobbs; W M Hanna; H Kahn; Maureen E Trudeau
The Henrietta Banting Breast Centre database: a model for clinical research utilizing a hospital-based inception cohort.
Journal of clinical epidemiology 1995;48(6):779-86.
1995: George Browman; Mark N Levine; E Ann Mohide; R S Hayward; Kathleen I Pritchard; A Gafni; A Laupacis
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):502-12.
1994: Mark Levine; J Hirsh; M Gent; A Arnold; David Warr; A Falanga; M Samosh; Vivien H C Bramwell; Kathleen I Pritchard; D Stewart
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.
Lancet 1994;343(8902):886-9.
1993: T A Vandenberg; Kathleen I Pritchard; Elizabeth A Eisenhauer; M E Trudeau; B D Norris; P Lopez; S S Verma; R A Buckman; A Muldal
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(7):1241-4.
1993: Judith-Anne W Chapman; B G Mobbs; W M Hanna; Carol A Sawka; Kathleen I Pritchard; H Lavina A Lickley; Maureen E Trudeau; E D Ryan; T C Ooi; D J Sutherland
The standardization of estrogen receptors.
The Journal of steroid biochemistry and molecular biology 1993;45(5):367-73.
1992: Judith-Anne W Chapman; Maureen E Trudeau; Kathleen I Pritchard; Carol A Sawka; B G Mobbs; W M Hanna; H Kahn; David R McCready; L A Lickley
A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer.
Breast cancer research and treatment 1992;22(3):263-72.
1992: M E Trudeau; Kathleen I Pritchard
Adjuvant endocrine therapy of breast cancer.
Cancer treatment and research 1992;60():69-114.
1989: Kathleen I Pritchard; D J Sutherland
The use of endocrine therapy.
Hematology/oncology clinics of North America 1989;3(4):765-805.
1987: B G Mobbs; EB Fish; Kathleen I Pritchard; G Oldfield; W H Hanna
Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment.
European journal of cancer & clinical oncology 1987;23(6):819-26.